Guided by Foresight, our proprietary functional genomics platform, we are creating a pipeline of precision oncology treatments by finding and matching the right therapies to the right patients with the hardest to treat cancers.
The Foresight platform enables a repeatable approach to building the pipeline. We continuously identify and in-license new clinic-ready assets that have the potential to reach unaddressed patient populations with precision medicines.
We mainly focus on compounds that have passed Phase 1 trials and proved safe, for which the main challenge is to pinpoint which patient populations they will benefit most. We also consider pre-IND compounds where the biology is well understood and clinical trials are within sight.
We accommodate a wide range of partnering structures, with a focus on in-licensing compounds. To discuss a potential collaboration, please contact our business development team at: